Estrella Immunopharma, Inc. reported a net loss of approximately $4.8 million for the three months ended September 30, 2025, compared to a net loss of $3.4 million for the same period in 2024. For the nine months ended September 30, 2025, the company recorded a net loss of approximately $12.5 million, up from $7.8 million in the prior year. The increase in losses is attributed to higher research and development expenses, which rose to $4.2 million for the third quarter of 2025, compared to $2.8 million in the same quarter of 2024. For the nine-month period, research and development expenses totaled $10.2 million, significantly higher than the $6.4 million reported in 2024.
The company's total assets as of September 30, 2025, were approximately $3.5 million, an increase from $3.1 million at the end of 2024. Current liabilities surged to approximately $13.4 million, up from $3.0 million at the end of the previous fiscal year, primarily due to accrued liabilities related to clinical trial services. The accumulated deficit also widened to approximately $36.4 million as of September 30, 2025, reflecting the ongoing investment in research and development without any revenue generation.
Estrella Immunopharma has been actively advancing its clinical programs, particularly the STARLIGHT-1 clinical trial for its product candidate EB103, a T-cell therapy targeting CD19. As of the end of September 2025, the company had dosed nine patients and activated a second clinical trial site. The company has incurred significant costs related to these clinical activities, with approximately $12.9 million accrued in liabilities for related party transactions, primarily with Eureka Therapeutics, which provides clinical trial services.
In terms of financing, Estrella raised approximately $2.4 million through various stock purchase agreements from May to September 2025. The company has also entered into a Common Stock Purchase Agreement with White Lion, allowing it to sell up to $50 million in shares, although stockholder approval is required for any issuance that would exceed 20% of the company's outstanding shares. As of September 30, 2025, the company had approximately $1.6 million in cash, which it expects to utilize for ongoing operational needs and clinical development.
Looking ahead, Estrella anticipates that its expenses will continue to rise as it progresses with its clinical trials and seeks regulatory approvals for its product candidates. The company has not generated any revenue to date and does not expect to do so for the foreseeable future, emphasizing the need for additional financing to support its operations and development efforts.
About Estrella Immunopharma, Inc.
Estrella Immunopharma is a biopharmaceutical company focused on developing T-cell therapies for cancer and autoimmune diseases. Its core platform, ARTEMIS, enables targeted, regulated immune responses to treat hematologic malignancies and solid tumors, with an emphasis on safety and efficacy. The company leverages innovative T-cell engineering to address limitations of existing immunotherapies, aiming to provide safer, more effective treatments for patients worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.